Sanofi, Owkin partner to develop next-generation biopharma AI agents

Sanofi has entered a multi-year agreement with Paris-based agentic AI company Owkin to co-develop next-generation AI-driven biopharma agents. The partnership includes a five-year licence for Owkin’s K Pro, an AI platform designed to augment drug discovery. Owkin will oversee the end-to-end construction of new agentic AI tools, specifically tailored for Sanofi’s needs. Credit: Gorodenkoff / Shutterstock.com. Sanofi has entered a multi-year agreement with France-based agentic AI company Owkin to co-develop next-generation AI-driven biopharma agents. The partnership includes a five-year licence for Owkin’s K Pro, an AI platform designed to augment drug discovery and development. Immuno-oncology (IO) Thematic Intelligence Reports…

Source: Pharmaceutical Technology